See more : Sunsweet Public Company Limited (SUN.BK) Income Statement Analysis – Financial Results
Complete financial analysis of RedHill Biopharma Ltd. (RDHL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RedHill Biopharma Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Luckin Coffee Inc. (LKNCY) Income Statement Analysis – Financial Results
- Birchcliff Energy Ltd. (BIR-PA.TO) Income Statement Analysis – Financial Results
- Kyowa Corporation (6570.T) Income Statement Analysis – Financial Results
- High Roller Technologies, Inc. (ROLR) Income Statement Analysis – Financial Results
- Interlink Communication Public Company Limited (ILINK.BK) Income Statement Analysis – Financial Results
RedHill Biopharma Ltd. (RDHL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.redhillbio.com
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.51M | 61.80M | 85.76M | 64.36M | 6.29M | 8.36M | 4.01M | 101.00K | 3.00K | 7.01M | 12.00K | 16.00K | 23.00K | 0.00 |
| Cost of Revenue | 3.46M | 33.34M | 49.41M | 36.89M | 2.26M | 2.84M | 2.13M | 30.54M | 22.00M | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.05M | 28.46M | 36.35M | 27.47M | 4.03M | 5.52M | 1.88M | -30.44M | -22.00M | 5.96M | 12.00K | 16.00K | 23.00K | 0.00 |
| Gross Profit Ratio | 46.89% | 46.06% | 42.39% | 42.68% | 64.09% | 66.06% | 46.94% | -30,140.59% | -733,300.00% | 85.03% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 3.52M | 7.28M | 29.50M | 16.49M | 17.42M | 24.86M | 32.97M | 25.24M | 17.77M | 12.70M | 8.10M | 6.46M | 5.41M | 736.00K |
| General & Administrative | 28.88M | 54.97M | 76.60M | 25.38M | 11.48M | 7.51M | 8.03M | 5.40M | 4.13M | 4.01M | 2.68M | 2.60M | 2.48M | 518.00K |
| Selling & Marketing | 2.10M | 9.06M | 11.39M | 49.29M | 18.33M | 12.49M | 12.01M | 1.56M | 1.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.98M | 64.03M | 87.99M | 74.66M | 29.81M | 19.99M | 20.04M | 5.40M | 4.13M | 4.01M | 2.68M | 2.60M | 2.48M | 518.00K |
| Other Expenses | -44.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 845.00K | 0.00 | 100.00K | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -9.56M | 71.31M | 117.49M | 91.15M | 47.23M | 44.85M | 53.85M | 30.64M | 22.01M | 16.61M | 10.78M | 9.06M | 7.90M | 1.73M |
| Cost & Expenses | -6.10M | 104.64M | 166.89M | 128.04M | 49.49M | 47.69M | 55.98M | 30.64M | 22.01M | 17.66M | 10.78M | 9.06M | 7.90M | 1.73M |
| Interest Income | 93.76K | 140.00K | 51.00K | 270.00K | 1.34M | 678.00K | 6.51M | 1.55M | 1.12M | 319.00K | 158.00K | 119.00K | 14.00K | 2.00K |
| Interest Expense | 367.00K | 41.33M | 16.57M | 12.76M | 438.00K | 167.00K | 77.00K | 375.00K | 212.00K | 383.00K | 14.00K | 1.48M | 65.00K | 876.00K |
| Depreciation & Amortization | 1.99M | 8.12M | 18.16M | 8.81M | 1.22M | 89.71K | 81.57K | 44.14K | 36.00K | 27.00K | 24.00K | 24.00K | 15.00K | -63.00K |
| EBITDA | 26.31M | -42.84M | -63.03M | -54.94M | -40.78M | -38.60M | -45.79M | -30.50M | -21.87M | -10.62M | -10.75M | -9.02M | -7.86M | -2.55M |
| EBITDA Ratio | 403.94% | -56.00% | -73.46% | -84.94% | -646.21% | -461.28% | -1,132.67% | -28,664.36% | -694,733.33% | -146.86% | -88,250.00% | -56,837.50% | -36,456.52% | 0.00% |
| Operating Income | 12.63M | -42.84M | -81.14M | -63.68M | -43.20M | -39.33M | -51.97M | -30.54M | -22.00M | -10.65M | -10.77M | -9.04M | -7.87M | -1.73M |
| Operating Income Ratio | 193.95% | -69.33% | -94.61% | -98.95% | -686.71% | -470.47% | -1,297.03% | -30,240.59% | -733,400.00% | -151.80% | -89,766.67% | -56,500.00% | -34,230.43% | 0.00% |
| Total Other Income/Expenses | 11.32M | -28.83M | -16.61M | -12.49M | 897.00K | 511.00K | 6.43M | 1.17M | 812.00K | -64.00K | 144.00K | -1.29M | -7.63M | -811.00K |
| Income Before Tax | 23.95M | -71.67M | -97.74M | -76.17M | -42.30M | -38.82M | -45.54M | -29.37M | -21.09M | -10.71M | -10.63M | -10.33M | -15.50M | -2.54M |
| Income Before Tax Ratio | 367.75% | -115.97% | -113.98% | -118.36% | -672.45% | -464.35% | -1,136.61% | -29,079.21% | -703,000.00% | -152.71% | -88,566.67% | -64,537.50% | -67,404.35% | 0.00% |
| Income Tax Expense | 0.00 | -12.42M | 16.57M | 12.84M | 1.33M | 727.00K | 6.29M | 1.27M | 900.00K | 222.00K | 142.00K | 1.29M | 7.63M | 874.00K |
| Net Income | 23.92M | -59.25M | -114.31M | -89.02M | -43.63M | -38.82M | -45.54M | -29.37M | -21.09M | -10.71M | -10.63M | -10.33M | -15.50M | -2.54M |
| Net Income Ratio | 367.19% | -95.87% | -133.30% | -138.31% | -693.59% | -464.35% | -1,136.61% | -29,079.21% | -703,000.00% | -152.71% | -88,566.67% | -64,537.50% | -67,404.35% | 0.00% |
| EPS | 3.69 | -38.27 | -98.27 | -97.75 | -58.78 | -68.00 | -104.00 | -94.96 | -76.13 | -49.47 | -68.15 | -80.00 | -128.96 | -19.35 |
| EPS Diluted | 3.69 | -38.27 | -98.27 | -97.75 | -58.78 | -68.00 | -104.00 | -92.00 | -75.51 | -49.12 | -68.15 | -78.53 | -128.96 | -19.35 |
| Weighted Avg Shares Out | 6.48M | 1.55M | 1.16M | 910.69K | 742.30K | 570.88K | 437.92K | 309.30K | 277.04K | 216.53K | 155.95K | 129.08K | 120.22K | 131.49K |
| Weighted Avg Shares Out (Dil) | 6.48M | 1.55M | 1.16M | 910.69K | 742.30K | 570.88K | 437.92K | 319.24K | 279.29K | 218.06K | 155.95K | 131.49K | 120.22K | 131.49K |
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
RedHill Announces FDA sNDA Approval for Talicia®
RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
RedHill Biopharma's stock soars 10% after company gets U.S. funding to develop treatment for radiation sickness
Source: https://incomestatements.info
Category: Stock Reports